ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Dabrafenib plus trametinib in patients with BRAFThe Lancet. Oncology · 2017Trial
- Molecular Characterization of Hotspot Mutations in HER2, BRAF, KRAS, and PIK3CA in Canine Pulmonary Adenocarcinoma from Japan.Veterinary sciences · 2026Article
- Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study.The oncologist · 2026Article
- Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies.Seminars in cancer biology · 2025Review
- Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma.International journal of molecular sciences · 2025Review
- Precision Oncology in Melanoma: Changing Practices.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Review
- A cytosolic mutp53(E285K) variant confers chemoresistance of malignant melanoma.Cell death & disease · 2023Article
- Current Patterns of Treatment and Outcomes in Advanced Melanoma at a Single Institution.The Journal of surgical research · 2023Article
- Association of CDKN2A alterations with increased postoperative seizure risk after resection of brain metastases.Neurosurgical focus · 2023Article
- Review
- International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers.Annals of surgery · 2023Article
- Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.Frontiers in oncology · 2023Article
- Targeted Therapy for Melanomas Without BRAF V600 Mutation.Current oncology reports · 2022Review
- Article
- Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant melanoma.Cell death & disease · 2022Article
- Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection.Annals of surgical oncology · 2021Article
- Unraveling the Wide Spectrum of Melanoma Biomarkers.Diagnostics (Basel, Switzerland) · 2021Review
- The Pan-Immune-Inflammation Value in Patients with Metastatic Melanoma Receiving First-Line Therapy.Targeted oncology · 2021Article
- Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.American journal of clinical dermatology · 2021Review
Corrections and comments
- Erratum for
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.